Article

Functional Personalized Treatment of Metastatic Porocarcinoma

2023-05-14

Abstract excerpt

<h4>Summary</h4> Metastatic porocarcinomas (PC) have high mortality rates of 70%. PC is extremely rare, accounting for 0.01% of malignant cutaneous neoplasms, precluding the possibility of conducting clinical trials to evaluate treatment. Pathogenesis and clinical management of PC remain largely unknown Surgical resection of localized PC remains the mainstay of treatment. There are no effective agents for unresect...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f42c2f3-ff82-5580-b088-de27e0582fd3
DOI: 10.1101/2023.05.09.23289625

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Functional Personalized Treatment of Metastatic PorocarcinomaDOI 10.1101/2023.05.09.23289625Read

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.Semantic proximity Read

Identification of potentially druggable molecular alterations in skin adnexal malignanciesSemantic proximity Read

Lesionalized therapy beyond personalized therapy in cancer management.Semantic proximity Read

Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromasSemantic proximity Read

Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.Semantic proximity Read

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity Read

Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma.Semantic proximity Read

Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinomaSemantic proximity Read

Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.Semantic proximity Read

Genomic Landscape of Lymphatic Malformations: A Case Series and Response to the PI3Kα Inhibitor Alpelisib in an N-of-One Clinical TrialSemantic proximity Read

Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.Semantic proximity Read

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.Semantic proximity Read